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1. Introduction
The replacement and healing of nonfunctional tissues has 
become a major challenge worldwide, due to the increase in 
life expectancy and the prevalence of age-related diseases. In 
the case of osteoarticular conditions, >1 million total knee 
and hip replacement surgeries were performed in 2010 in the 
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United States,[1,2] and projections indi-
cate that the number of primary and 
revision joint arthroplasties will grow 
significantly in coming years;[3] similar 
statistics are also found in Europe.[4,5] 
However, and despite the intrinsic capacity 
of bone to regenerate after injury, com-
plete fracture healing and implant fixation 
are not always possible.[6,7] Thus, joint 
replacements still fail at unacceptable rates, 
with some reports describing revision rates 
as high as 17.5% for total hip arthroplasty.[8]
Successful implant fixation and full 
recovery of lost function depend on many 
factors, which include patient character-
istics (e.g., age, alcohol consumption, 
smoking habits, metabolic conditions), 
factors associated with the implantation 
site (e.g., injury and infection at the site, 
poor vascularization), and those related to 
the surgical procedure and implant properties.[9] Nonetheless, 
it is increasingly accepted that the two major causes of implant 
failure are aseptic loosening and infection.[10] For example, a 
recent epidemiologic study indicates that mechanical loosening 
(20.3%) and infection (20.4%) were the most common etiology 
for revision of total knee arthroplasty in the United States 
between 2009 and 2013.[11]
Incomplete osteointegration (i.e., not achieving a strong and 
durable connection between periimplant bone and the implant 
surface)[12] represents a major contribution toward aseptic loos-
ening. Although Brånemark’s description of osteointegration 
originally referred to titanium (Ti) dental implants, it is nowa-
days widely used for orthopedic implants as well. Osteointegra-
tion relies on i) mechanical interdigitation, which ensures the 
primary fixation of the implant with bone after surgery, and ii) 
cellular interactions at the surface level, which are responsible 
of promoting osteoconduction, osteoinduction, and healing 
during the first 3–4 months.[13] Both processes are crucial to 
ensure an optimal clinical outcome, i.e., bone healing, allowing 
the recovery of lost function and patient’s mobility.
Implant infection also represents a major concern.[14,15] In 
fact, postimplantation, patients are more susceptible to infec-
tion. This increased vulnerability relates to the fact that the 
efficacy of the immune system is locally reduced by the pres-
ence of a foreign body (e.g., a metallic implant) and to the 
predilection of bacteria to adhere to solid substrates.[16] Thus, 
it only takes a few adherent bacteria to attach to the implant 
surface, grow and multiply to form a biofilm.[17,18] This pro-
cess is usually initiated by planktonic bacteria, which act 
as primary colonizers, and is followed by a second phase, in 
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which secondary (or late) colonizers are irreversibly bound to 
the surface and create a biofilm. Once established, biofilms are 
highly resistant to the immune system and conventional drugs, 
such as antibiotics, and may also spread and infect other tis-
sues. This further affects patient morbidity and even results in 
death in severe cases.[19–22] Moreover, the emergence of antibi-
otic resistance, e.g., methicillin-resistant Staphylococcus aureus 
(MRSA), poses a serious threat.[14,19,23] Although the numbers 
vary greatly depending on the surgical procedure and the type 
of device, infection of orthopedic implants may occur in up to 
5% of cases.[9] In the case of dental implants, infection rates 
are higher, reaching values of peri-implantitis or dental implant 
infections as high as 14%.[24]
It is therefore not surprising that extensive research is being 
performed to tackle these two problems, and a large number of 
strategies of surface modification have been described to either 
improve implant osteointegration[9,13,25–29] or reduce bacterial 
infection.[9,14,24,30–34] However, the necessity of simultaneously 
addressing both these limitations has only been highlighted 
recently.[10,35–37]
The development of multifunctional strategies that promote 
osteointegration while mitigating bacterial colonization is clearly 
important because both effects are necessary to ensure an optimal, 
long-term functionality of medical implants. However, we note 
that this notion is not new. Already in the late 1980s, the attach-
ment of host cells and bacteria to the implant surface was defined 
as a competitive “race for the surface.”[38] In such a scenario, the 
winner takes it all. If host eukaryotic cells colonize the implant and 
proliferate faster, the resulting adherent cell layer will discourage 
bacterial attachment and reduce the risk of infection. By contrast, 
if bacteria are able to adhere and produce biofilms, the osteointe-
gration of the implant will be seriously compromised.
Further, classical approaches focusing only on improving 
one biological effect might paradoxically be detrimental for 
the other. Implant surfaces that promote osteointegration (e.g., 
rough surfaces) may also facilitate an increased bacterial attach-
ment. Conversely, bactericidal agents used to inhibit bacterial 
infection may be toxic or impair normal host cell functions.[9,10]
The aim of this review is to provide an overview of the 
existing strategies of surface modification that simultaneously 
combine cell adhesive/osteoinductive and antibacterial prop-
erties. Implants with such multifunctional potential would 
accelerate implant osteointegration and healing but minimize 
the risk of early/late infections—thus improving their clin-
ical outcome and reducing the number of revision surgeries. 
To this end, this review particularly focuses on two emerging 
solutions, the use of multifunctional chemical coatings and 
nanotopographical features.
2. Classical Strategies and Limitations
2.1. Strategies to Improve Osteointegration
Improvement of the implant’s bioactivity toward enhanced 
levels of osteointegration has been classically addressed 
by physical and chemical methods of surface modification 
(Figure 1A), and several reviews comprehensively covering 
these approaches are available.[9,13,25–29]
Physical methods have largely focused on increasing the 
average roughness (Ra) of the implant surface, following experi-
mental evidence in vivo that substrates with higher Ra were 
capable of achieving higher rates of osteointegration.[13,39] This 
observation may be due to higher micromechanical retention 
of bone on rougher substrates compared to smooth ones, and 
the positive influence of surface roughness on protein adsorp-
tion and osteoblastic function.[40–42] Increasing surface rough-
ness at the submillimeter–micrometer level can be easily 
achieved by several inexpensive methods, such as grit blasting 
or acid etching, and many dental implants nowadays display 
Ra values within 1–5 µm. The main limitation of nonspecifi-
cally increasing the surface roughness of an implant above a 
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certain threshold (some authors have defined this value as 
Ra > 0.2 µm)[43,44] is that such rougher surface will likely support 
higher levels of bacterial attachment as well (Table 1). Alterna-
tively, well-defined surface modifications at the nanotopographic 
level have emerged—and are now established—as a feasible 
way to control stem cell response and osteogenic differentiation. 
Topographical features at the nanoscale are not expected to pro-
mote bacterial attachment (i.e., they are below 0.2 µm) and can 
be tuned to even prevent infection. This subject will be covered 
with detail in Sections 4 and 5 of this review.
Chemical coatings generally try to mimic the extracellular 
matrix (ECM) of bone.[27] As such, inorganic coatings are often 
based on calcium phosphate (CaP)/hydroxyapatite (HAp), the 
mineral component of bone. Organic coatings, on the other 
hand, include cell adhesive proteins or peptides derived from 
the ECM. The deposition of CaP minerals to bioactivate implant 
surfaces has represented a main focus of 
research for more than 30 years now.[45,46] This 
was originally achieved by plasma spray and 
electrodeposition methods,[47,48] but concerns 
on the (poor) mechanical stability of thick CaP 
coatings were later reported.[49,50] To overcome 
this, biomimetic strategies were described 
during the 1990s. In general, these strate-
gies allowed the formation of thinner CaP 
layers, exhibiting high bioactivity and better 
mechanical properties.[51–57] A representative 
and successful example is the method deve-
loped by Kokubo et al.,[51,58] which combines a 
basic etching and a thermal treatment of Ti to 
produce an amorphous sodium titanate layer. 
Immersion of treated surfaces into physi-
ological buffers (i.e., simulated body fluid) 
drives the nucleation of bone-like apatite, thus 
conferring bioactivity to the material. Interest-
ingly, this method has shown good versatility 
and can be applied to other medically relevant 
materials, including niobium, tantalum, and 
zirconium.[59–61]
These coatings are highly osteoconductive 
and have shown osteointegrative potential 
in vivo.[9,13] According to some authors, CaP 
materials are osteoinductive as well, which 
may be attributed to their capacity to adsorb 
proteins such as growth factors (GFs). In this regard, both their 
chemistry and specific surface area can be tuned to efficiently 
immobilize bone morphogenetic proteins (BMPs)—yet it is 
plausible that these characteristics (i.e., high specific surface 
area) may concomitantly favor bacterial adhesion (Table 1).[62] A 
potential solution to that is to use CaP coatings as drug delivery 
systems (e.g., loaded with antibacterial agents),[63] so the bioac-
tivity of CaP can be combined with antibacterial properties (this 
strategy will be discussed in Section 3.2).
Organic coatings include a diverse range of molecules, from 
polymers to proteins, peptides, or small organic molecules.[13,64] 
In general, this strategy has focused on proteins from bone 
ECM, with fibronectin, vitronectin, and collagens being rep-
resentative examples.[27,28,65] The majority of ECM proteins 
support cell attachment via cell adhesive motifs such as the 
RGD sequence,[66,67] which recognizes and binds to integrin 
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Figure 1. Schematic summary of classical strategies of surface functionalization. A) Improve-
ment of osteointegration can be achieved by physical methods, which commonly focus on 
modifying the surface topography (e.g., surface roughness), or chemical methods, which are 
based on inorganic (e.g., calcium phosphate) or organic (e.g., peptide and protein) coatings. 
B) The strategies to inhibit bacterial infection can be divided into passive (e.g., antiadhesive) 
or active (e.g., drug eluting or immobilized) coatings.
Table 1. Summary of classical strategies of surface functionalization of biomaterials, main effect targeted and potential nonwanted effects.
Strategy Main effect targeted Limitation
Increasing surface roughness (e.g., Ra in the µm range) Improvement of osteointegration by  
higher mechanical retention
Rough surfaces (e.g., >0.2 µm) may also increase 
bacterial attachment
Inorganic coatings based on CaP/bone-like apatite Providing osteoconductive/osteoinductive potential 
to improve osteointegration
Higher specific surface area of CaP may also 
increase bacterial attachment
Organic coatings based on proteins/peptides 
from the ECM
Providing osteoconductive/osteoinductive 
potential to improve osteointegration
Bacteria share cell adhesion mechanisms with 
eukaryotic cells (using ECM molecules)
Antiadhesive coatings Inhibiting/repelling bacterial attachment Eukaryotic cell attachment is also  
compromised (inhibited)
Bactericidal coatings (release-based and 
nonrelease-based)
Killing bacteria/inhibiting bacterial attachment Eukaryotic cell attachment, functions, and viability 
may be also compromised
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receptors expressed by eukaryotic cells.[68] Integrin (and nonin-
tegrin) binding ligands have thus been frequently used not only 
to improve cell adhesion but also to stimulate cell proliferation 
and differentiation.[69,70] As the use of native ECM proteins 
and synthetic peptides entails limitations of stability, biological 
potency, and specificity (these issues still remain controver-
sial),[71–73] advances in this field have focused on recombinant 
protein fragments,[74–77] multifunctional peptides,[78–80] and 
nonpeptidic ligands.[70,81]
Inducing integrin signaling cascades has become a common 
strategy to improve bone healing. However, to optimally mimic 
the cellular microenvironment on the biomaterial surface, 
signaling through other mechanisms is required. For instance, 
several GFs such as BMPs[82] are known to cooperate with integrin 
ligands to regulate bone regeneration. In this regard, a growing 
body of evidence indicates that GF signaling can be regulated 
and enhanced by dynamic crosstalk with integrin receptors.[83–85] 
In particular, recent examples have shown that the combination 
of ECM proteins with BMPs has a synergistic effect to induce 
stronger osteogenic signals and bone formation in vivo with 
reduced doses of GF.[86–89] These approaches are of relevance and 
constitute a hot topic of research, as they take advantage of the 
osteoinductive potential of BMPs while overcoming the compli-
cations and concerns associated to their use.[90,91] Further infor-
mation is available in the recent literature.[35,84,85]
Functionalization of medical implants with molecules from 
the ECM appears to provide a strategy that should not pro-
mote bacterial colonization. However, organic coatings are 
not exempt from risks either. For example, the production of 
proteins (or fragments) by recombinant methods is commonly 
done using bacterial systems. Such methods inherently entail 
the risk of introducing remnants of bacteria (e.g., endotoxins) 
on the biomaterial surface during the coating procedure. In 
addition, bacteria share similar adhesion mechanisms with 
eukaryotic cells to attach to surfaces, and may bind to ECM 
proteins such as fibronectin[92,93] or collagens.[94]
Finally, it should be mentioned that the aforementioned 
strategies (e.g., surface roughness and bioactive coatings) can 
be combined to achieve synergistic effects and improved bio-
logical responses. For example, grit blasting of titanium sur-
faces,[95] followed by alkaline etching and thermal treatments 
(a method named 2Step), showed accelerated in vitro formation 
of bioactive apatite on the bottom of the topographical valleys 
in comparison to smooth surfaces.[96] This treatment showed 
improved differentiation of human osteoblastic cells in vitro[97] 
and enhanced bone formation in vivo.[13,98] Another study eval-
uated the combination of different levels of surface roughness 
with a cyclic RGD peptide. Interestingly, the highest levels of 
cell adhesion were obtained on the rougher surfaces function-
alized with the peptide, compared to peptide-coated smooth 
surfaces or nonfunctionalized controls (smooth and rough).[99]
2.2. Strategies to Inhibit Bacterial Infection
The number of strategies investigated to fight bacterial infec-
tion is also growing, and this field represents a very active 
area of research in the biomaterials community.[9,14,24,30–34] 
Although a myriad of methods have been described, a common 
classification is to divide antibacterial treatments as passive 
or active, depending on their ability to discourage bacterial 
cell attachment or actually kill contaminating bacteria, respec-
tively. Active coatings may rely on the release of antibacterial 
agents (release-based) or surface strategies (nonrelease-based) 
(Figure 1B). Regardless of classification, the goal is always the 
same: inhibit bacterial adhesion on the surface and prevent the 
formation of highly resistant biofilms.
Passive coatings are typically based on antiadhesive polymers 
that prevent protein and cellular (e.g., bacteria) attachment. 
Alternatively, such antifouling effect can also be achieved 
using nanotopographies (see Section 5.1). Among all polymers, 
polyethylene glycol (PEG) is probably the most widely used to 
confer antifouling properties to a material surface.[30,100] Its 
repelling properties are related to its flexible and hydrophilic 
chains. These chains form a wide exclusion volume that blocks 
protein adsorption and cell attachment. Other examples of low 
fouling polymers include poly(methacrylic acid) (PMAA), dex-
tran, or hyaluronic acid.[36] Such coatings can easily be applied 
to a broad range of materials and have the advantage of being 
simple, effective, and not requiring the use of drugs. However, 
the main strength of antiadhesive coatings represents a con-
comitant weakness, as very efficient bacteria repelling coatings 
will inhibit eukaryotic cell attachment as well. For this reason, 
antifouling polymers often require the incorporation of cell 
adhesive sequences to preserve cell adhesion and the biomate-
rial’s functionality. Such strategy represents a clear example of 
multifunctional coating and is described later in Section 3.1.
In contrast to passive coatings, active coatings exert their 
antibacterial action by directly killing bacteria. This may be 
achieved by a very diverse range of molecules, including bacte-
ricidal polymers (e.g., chitosan, cationic polymers), quaternary 
ammonium salts, ions (e.g., silver, zinc), antibiotics, bacteri-
cidal agents (e.g., chlorhexidine), and antimicrobial peptides 
(AMPs).[9,14,24,31–34] These strategies are largely reliant upon two 
physicochemical approaches: i) the incorporation of antibacte-
rial agents (e.g., antibiotics or silver ions) on the biomaterial 
via physical adsorption or entrapment in polymeric matrices 
(drug-releasing mechanism), and ii) the covalent functionaliza-
tion of the materials with bactericidal molecules (e.g., AMPs). 
Although drug-releasing approaches are commonly applied and 
have proven their efficacy in many reports, the second approach 
(i.e., immobilization of the antibacterial molecule) warrants fur-
ther research because the release of antibacterial agents entails 
several risks in terms of (off target) toxicity, rapid dwindling 
concentration due to release and loss of activity over time; these 
latter effects necessitate the use of very high doses, increasing 
toxicity and increasing probability of bacterial resistance.
In particular, the emergence of antimicrobial resistance 
mechanisms in bacteria severely compromises the use of anti-
biotics and other antibacterial drugs.[101,102] For instance, the 
highly virulent multidrug resistant strains of S. aureus (e.g., 
MRSA) establish dangerous infections that in many instances 
are very difficult or impossible to treat with existing medi-
cines.[103] These bacteria, also known as “superbugs,” are con-
sidered one of the most frequent causes of healthcare-associated 
infections worldwide and are responsible for a high mortality 
rate. As mentioned before, on biomaterial-associated infections, 
the picture is further complicated by the growth of biofilms, 
Adv. Healthcare Mater. 2019, 8, 1801103
www.advancedsciencenews.com www.advhealthmat.de
1801103 (5 of 26) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
exacerbating the antibiotic resistance scenario. Furthermore, it 
has also been described that the release of antibacterial agents 
such as silver or antibiotics may negatively affect osteoblastic 
functions as well (Table 1).[104,105]
3. Multifunctional Chemical Coatings
The functionality of biomaterials can be significantly improved 
by either enhancing their interaction with eukaryotic cells (e.g., 
osteoblasts—improved osteointegration) or inhibiting bacterial 
infection. However, specifically improving host cell adhesion 
while inhibiting bacterial attachment is a challenging task. As a 
matter of fact, most approaches intended to confer osteoinduc-
tive properties to biomaterials have not considered the risk of 
bacterial colonization. Or worse, treatments or surface modifi-
cations that facilitate cell adhesion and proliferation may also 
favor bacterial attachment and biofilm formation. Conversely, 
research efforts devoted to inhibit bacterial colonization are 
often related to antiadhesive polymers or cytotoxic agents that 
may compromise osteoblast-like cell functions.
In this section, we will focus on coatings composed of dis-
tinct chemical entities (e.g., materials, biomolecules, or drugs), 
which are combined in a way that a dual function (i.e., oste-
ointegrative and antibacterial) is achieved. These strategies 
are normally not intended to modify the properties of the 
bulk material, only its surface, and hence are categorized as 
strategies of surface functionalization. Although the number of 
examples in the literature is rapidly increasing and a myriad of 
combinations are possible, we will center this section according 
to three differentiated approaches: i) antibacterial coatings func-
tionalized with cell instructive molecules; ii) osteoconductive/
osteoinductive coatings loaded with antibacterial agents; and iii) 
immobilized multifunctional peptides (Figure 2 and Table 2).
3.1. Coatings Based on Antibacterial Polymers
3.1.1. Functionalized Antiadhesive Polymers
The first approach to achieve cell instructive and antibac-
terial effects focuses on the use of antifouling polymers 
functionalized with cell adhesive peptides (Figure 2A). It is 
plausible that this strategy was originally not conceived as a 
multifunctional coating, but that it responded to the inherent 
limitations of antifouling polymers like PEG. As previously 
outlined, PEG is very efficient in preventing bacterial attach-
ment, but it also blocks the adhesion of wanted host cells—as a 
matter of fact, PEG is frequently used to reduce nonspecific cell 
binding in cellular and biophysical studies. Thus, the incorpo-
ration of a cell adhesive sequence such as RGD is required to 
maintain cell-binding properties.
To the best of our knowledge, the first report following this 
strategy was published by Harris et al. in 2004 (Table 2).[106] In 
this work, PEG was electrostatically adsorbed on Ti surfaces 
using poly-L-lysine (PLL), and the PEG-PLL copolymer was fur-
ther functionalized with an RGD peptide using vinyl sulfone-thiol 
chemistry. The PEG coating significantly reduced the attach-
ment of S. aureus, and, of note, the presence of the RGD pep-
tide did not affect the antibacterial activity. In a subsequent study, 
the same group showed a reduced attachment of other medi-
cally relevant bacterial strains (e.g., Staphylococcus epidermidis, 
Streptococcus mutans, and Pseudomonas aeruginosa).[107] However, 
the authors did not check the response of eukaryotic cells to the 
RGD peptide on these studies. Both effects were actually reported 
in other investigations, which reflected the multifunctional poten-
tial of this strategy: the passive PEG layer inhibited bacterial 
attachment, while the RGD peptide simultaneously supported (or 
improved) osteoblast (OB)[108] or fibroblast (FB)[109] adhesion. In 
addition to electrostatic adsorption, a number of other methods 
have been proposed to coat Ti surfaces with PEG, such as electro-
deposition, silanization, and plasma polymerization.[109]
This technique is facile and versatile, as it can be expanded 
using different antifouling polymers and bioactive sequences. 
For instance, PMAA, dextran, or hyaluronic acid have been com-
bined with cell adhesive sequences (e.g., RGD, silk sericin) or GFs 
(e.g., BMP-2, vascular endothelial growth factor (VEGF)) demon-
strating excellent dual potential (see Table 2 for details).[110–112]
Recent studies have further combined the antiadhesive 
properties of PEG and other polymers with bactericidal agents 
(e.g., quaternary ammonium compounds, ions, AMPs, or 
bactericidal polymers) to simultaneously exploit passive and 
active antibacterial mechanisms.[113–119] Such dual antibacte-
rial function aims at both preventing bacterial attachment and 
killing bacteria able to adhere. This approach is also interesting 
because it inhibits the accumulation of bacterial debris and pro-
teins, which may provide anchoring points for the formation of 
biofilms. These works, however, do not address eukaryotic cell 
adhesion—crucial to ensure implant integration with tissues—
and will not be covered in this review.
The major limitation of using polymers to coat substrates 
is the risk of polymer degradation over time. Degradation may 
compromise the long-term stability and prolonged effect of the 
coatings. Moreover, their fabrication and obtaining of defined 
and homogenous structures may be challenging.
3.1.2. Functionalized Bactericidal Polymers
An alternative strategy to antiadhesive coatings like PEG is 
to use polymeric coatings that are directly bactericidal. One 
canonical example is chitosan, which is well known for its anti-
bacterial properties.[120] Although this polymer has been also 
attributed with good biocompatibility and cell adhesive activity, 
several reports have combined chitosan with cell adhesive pep-
tides to achieve a dual effect; examples are provided in Table 2. 
For instance, Neoh and co-workers adsorbed polyelectrolyte 
multilayers of chitosan and hyaluronic acid on Ti, and anchored 
an RGD peptide to the external chitosan layer via carbodiimide 
chemistry. The resulting surfaces inhibited S. aureus adhesion 
while improving osteoblastic responses (adhesion, proliferation, 
and alkaline phosphatase (ALP) activity).[121] In a parallel study, 
the same authors reported the covalent immobilization of RGD-
coated chitosan with very similar biological results.[122] In this 
case, Ti was sequentially modified with dopamine (which binds 
to Ti via the catechol moiety) and glutaraldehyde, rendering a 
free aldehyde group on the surface that was used to covalently 
bind chitosan by reductive amination. The RGD sequence was 
finally grafted using carbodiimide chemistry. Another viable 
Adv. Healthcare Mater. 2019, 8, 1801103
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solution is to immobilize GFs or enzymes onto chitosan layers 
to improve cell adhesion and also osteogenic differentiation. 
This has been achieved combining chitosan or carboxymethyl 
chitosan with BMP-2,[123,124] VEGF,[112] or ALP[125] (see Table 2 
for details). The biological potential of chitosan can be further 
increased with other antibacterial agents. In a recent study, 
the combination of chitosan with gallium effectively decreased 
Escherichia coli and P. aeruginosa viability. Interestingly, gallium 
also showed a beneficial osteogenic effect.[126]
In addition to chitosan, a number of other antibacterial 
cationic polymers have been described, such as ε-poly-L-lysine 
(ε-PLL), quaternary ammonium polymers, polyethylenimine, 
and polyguanidines.[127] Among them, ε-PLL has shown a 
broad spectrum of antimicrobial activity against Gram-negative 
and Gram-positive bacteria but low toxicity for eukaryotic 
cells.[127,128] Taking advantage of this, ε-PLL-based hydrogels 
with wound healing and anti-infective properties have been 
developed.[129,130] As positively charged polymers easily adsorb 
electrostatically on oxidized metallic surfaces, it is expected that 
these polymers may also be used as multifunctional coatings 
on orthopedic implants.
3.2. Osteoconductive/Osteoinductive Surfaces Loaded with 
Antibacterial Agents
A conceptually similar but inverse approach is to use surfaces 
that have osteoconductive or osteoinductive potential. Coatings 
Adv. Healthcare Mater. 2019, 8, 1801103
Figure 2. Schematic summary of multifunctional strategies to achieve both cell instructive and antibacterial properties. A) Antibacterial polymers can 
be used to either repel (antiadhesive, e.g., PEG) or kill (bactericidal, e.g., chitosan) bacteria; in both cases the presence of a cell adhesive sequence 
is required. B) The opposite approach is to use osteogenic surfaces (Ti dioxide nanotubes, TNTs, CaP coatings) or RGD-decorated nanoparticles that 
incorporate and release antibacterial agents (e.g., antibiotics, silver, AMPs). C) A third strategy is to covalently immobilize cell adhesive sequences and 
AMPs on the biomaterial surfaces. To this end, peptide mixtures or peptidic branched platforms can be used.
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Table 2. Selection of representative examples of multifunctional approaches on biomaterials.
Strategy Biofunctional elements Substrate + coatings (immobilization method)a) Main biological effectsb) References
Functionalized 
antiadhesive polymer
PEG + RGD Ti + PLL-g-PEG (electrostatic adsorption) + RGD (vinyl 
sulfone-thiol)
↓S. aureus adhesion; Cell adhesion not 
studied
[106]
PEG + RGD Ti + PLL-g-PEG (electrostatic adsorption) + RGD (vinyl 
sulfone-thiol)
↓Bacterial adhesion (several strains); Cell 
adhesion not studied
[107]
PEG + RGD Ti + PLL-g-PEG (electrostatic adsorption) + RGD (vinyl 
sulfone-thiol)
↓S. epidermidis adhesion; ↑ OB-like 
adhesion
[108]
PEG + RGD Ti + PEG (several methods) + RGD (physisorption) ↓S. sanguinis and L. salivarius adhesion; ↑ 
FB adhesion
[109]
Dextran + BMP-2 Ti6Al4V-dopamine + dextran (reductive amination) + BMP-2 
(reductive amination)
↓S. aureus and S. epidermidis; ↑ OB 
response
[110]
PMAA + silk sericin Ti + PMAA (silanization + SI-ATRP) + silk sericin 
(carbodiimide chemistry)
↓S. aureus and S. epidermidis adhesion; ↑ 
OB response
[111]
HA + VEGF Ti + catechol-HA (direct chemisorption) + VEGF 
(carbodiimide chemistry)
↓S. aureus adhesion; ↑ OB response [112]
Functionalized 
bactericidal polymer
CM-CH + VEGF Ti-dopamine + CM-CH (carbodiimide chemistry) + VEGF 
(carbodiimide chemistry)
↓S. aureus adhesion; ↑ OB response [112]
HA/CH + RGD Ti + HA/CH (PEMs electrostatic adsorption) + RGD 
(carbodiimide chemistry)
↓S. aureus adhesion; ↑ OB response [121]
CH + RGD Ti-dopamine + CH (glutaraldehyde crosslinking) + RGD 
(carbodiimide chemistry)
↓S. aureus and S. epidermidis adhesion; ↑ 
OB response
[122]
CM-CH + BMP-2 Ti6Al4V-dopamine + CM-CH (carbodiimide chemistry) + 
BMP-2 (carbodiimide chemistry)
↓S. aureus and S. epidermidis adhesion; ↑ 
OB and MSC response
[123]
CM-CH + ALP Ti-dopamine + CM-CH (carbodiimide chemistry) + ALP 
(carbodiimide chemistry)
↓S. epidermidis adhesion; ↑ OB, MSC and 
ADSC osteogenic differentiation
[125]
CH/PAA + Ga Ti + PAA (electropolymerization) + CH-Ga (electrochemical 
deposition)
↓E. coli and S. epidermidis viability; 
OB-like adhesion supported and ↑ 
BMP-2 expression
[126]
Osteoconductive/osteo-
inductive surface loaded 
w/antibacterial agents
TNT + Ag Ti > TNT (anodization) + Ag (electrodeposition) ↓P. aeruginosa adhesion; Biocompatible 
for OBs
[132]
TNT + Ag2O NPs Ti > TNT-Ag2O (TiAg magnetron sputtering and anodization) ↓S. aureus and E. coli; OB-like response 
not influenced compared to TNTs
[133]
TNT + Zn Ti > TNT (anodization) + Zn (hydrothermal treatment) ↓S. aureus adhesion and proliferation; ↑ 
OB-like response; ↑ Bone formation in 
vivo
[135]
TNT + gentamicin + CH/
PLGA
Ti > TNT (anodization) + gentamicin 
(drop casting) + CH/PLGA (dip coating)
↓S. epidermis viability; ↑ OB-like response [139]
HAp + Ag2O + SrO Ti + HAp/Ag2O/SrO (plasma spray) ↓P. aeruginosa viability; ↑ OB-like response 
for HAp + Ag/Sr compared to HAp
[150]
CaP + HHC36 Ti + HAp (electrolyte deposition) + HHC36 (physical 
adsorption)
↓P. aeruginosa and S. aureus viability; ↑ 
OB-like cell adhesion; ↑ Bone formation 
in vivo
[154]
cRGD + roxithromycin Ti + RGD-NPs/roxithromycin (silanization; roxithromycin is 
loaded by emulsification)
↓S. sanguinis adhesion; ↑ OB-like response [164]
BMP-2 + vancomycin Ti + BNP/BMP-2 + BNP/vancomycin (layer-by-layer 
adsorption; drugs are loaded by a desolvation method
↓S. epidermidis growth; ↑ BMSC response [166]
Immobilized peptides RGD + HHC36 Ti + RGD/HHC36 (silanization + click chemistry) ↓S. aureus and E. coli adhesion; ↑ BMSC 
adhesion
[178]
RGD + LF1-11 Ti + RGD/LF1-11 (silanization) ↓S. aureus and S. sanguinis; ↑ OB-like 
response
[181]
PEG + RGD + LF1-11 Ti + PEG (electrodeposition) + RGD/LF1-11 
(maleimide-thiol chemistry)
↓S. sanguinis; ↑ OB-like response [183]
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such as Ti dioxide nanotubes (TNTs) or CaP can be doped with 
antibacterial agents, such as antibiotics or cations.
TNTs represent a very attractive strategy in the biomedical 
field as they have excellent corrosion resistance and biocompat-
ibility. In particular, they have been described to improve osteo-
blastic functions and, in some cases, have antibacterial potential 
(although these effects are largely reliant on the TNTs geom-
etry and physicochemical properties).[131] On the basis of these 
interesting features, TNTs have been fabricated by different 
methods (e.g., template-assisted, anodization, or hydrother-
mally) and loaded with silver (either as ion[132] or nanoparti-
cles[133,134]), zinc,[135,136] copper,[137] or antibiotics.[138,139] Overall, 
this approach has shown good biocompatibility with OB-like 
cells, improved osteogenic responses, and reduced adhesion 
and viability of several bacterial strains (Table 2). For this type 
of system, a crucial parameter to control is the concentration of 
the molecule released, as it has been observed that the release 
of high concentrations of silver may be cytotoxic for several 
eukaryotic cell types (e.g., epithelial cells, FBs, and OBs),[133,140] 
and that high doses of ZnO and silver nanoparticles may 
decrease the antibacterial activity or even promote bacterial 
attachment.[141] Moreover, recent evidence has shown that cer-
tain bacterial isolates may develop resistance to silver.[142] Alter-
natively, TNTs can be engineered in a way that they support the 
adhesion of osteogenic cells but reduce bacterial attachment 
without the addition of ions (see Section 6 for details).[143,144]
A more classical approach would be to employ CaP coat-
ings, which are inherently osteoconductive, and load them with 
antibacterial agents. Here, silver is frequently used too.[145–149] 
For example, HAp coatings doped with Ag2O and SrO were 
plasma-sprayed onto Ti to incorporate bactericidal potential to 
the inorganic substrate. Interestingly, silver was highly effec-
tive against P. aeruginosa but the release of this ion was detri-
mental for the activity of OBs. Codoping the coating with SrO 
seemed to compensate this negative effect and rescued normal 
osteoblastic functions (Table 2).[150] Thus, the antibacterial 
potential of silver can be combined with the bioactivity of 
strontium within CaP-based coatings to improve Ti implants 
response; recent reports have further exploited such interesting 
multifunctional approach.[151,152] The limitations described for 
silver in the previous examples can be circumvented using 
other antibacterial agents. For example, AMPs (HHC36: KRW-
WKWWRR; Tet213: KRWWKWWRRC) have been incorporated 
into CaP coatings.[153,154] While Tet213 showed toxicity for OB-
like cells even at low concentrations, HHC36 displayed little 
toxicity. HHC36-CaP-coated Ti surfaces showed antibacterial 
potential against S. aureus and P. aeruginosa and improved 
levels of osteoconductivity in an in vivo model of trabecular 
bone growth using cylindrical implants in rabbits.[154] This 
study suggests that AMPs may be a good alternative to silver 
but also shows that the selection of the peptide is important 
(i.e., balancing good antibacterial activity with low toxicity 
for eukaryotic cells). Antibiotics have also been frequently 
combined with CaP coatings showing effective osteoconduc-
tivity and antibacterial properties.[63] Diverse examples of this 
strategy can be found in the literature and include the use 
of gentamicin,[155] vancomycin,[156,157] and its derivatives,[158] 
among others.
Regardless of the antibacterial agent used, a common limi-
tation of this approach is the burst release of the bactericide. 
Such rapid release may be deleterious for several reasons: i) it 
reduces the long-term effectiveness of the coatings; ii) a high 
concentration of drug may be toxic for host cells; and iii) it 
may promote bacterial resistance. A potential solution to this 
problem is to introduce polymeric coatings that cap and pro-
tect the coating, and that deliver the drug as they degrade, 
thus slowing down release kinetics. For example, this has been 
achieved with polylactic-co-glycolic acid (PLGA), which was used 
to control the delivery of the antibiotic clindamycin from dif-
ferent CaP coatings.[159] A similar polymeric coating was used 
to fine-tune the release of drugs from TNTs.[139] In this case, 
TNTs were loaded with gentamicin and subsequently covered 
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Strategy Biofunctional elements Substrate + coatings (immobilization method)a) Main biological effectsb) References
PF127 + RGD + AMP Silicon + PF127/PF127-RGD/PF127-AMP (physical 
adsorption)
↓S. aureus, S. epidermidis and P. aeruginosa 
adhesion; ↑ FB adhesion
[184]
EGF + magainin II PLGA + EGF (physical entrapment) + magainin II (carbodi-
imide chemistry)
↓S. aureus and E. coli adhesion; ↑ FB 
adhesion
[185]
Collagen-mimetic Ti + collagen-mimetic (physisorption) ↓S. aureus and S. epidermidis adhesion; ↑ 
OB-like adhesion and differentiation
[188]
TESPSA silane Ti + TESPSA (silanization) ↓S. sanguinis and L. salivarius adhesion; ↑ 
OB-like differentiation; ↑ FB adhesion
[189]
RGD + Phe(4-F) Ti + DOPA-peptide (chemisorption) ↓E. coli adhesion; ↑ OB-like adhesion [190]
a)“Substrate” refers to the material used, and “coating” to the combination of chemical entities that exhibit multiple biological activity; the methods used to immobilize 
the coatings are described in brackets; b)Only the main biological effects are highlighted. Reduced bacterial adhesion commonly indicates a reduction in bacterial cell 
numbers compared to controls. Improved cell response usually refers to increased values of cell adhesion, proliferation and differentiation compared to controls. Detailed 
data can be found in the corresponding references. Abbreviations used: ADSC = adipose-derived stem cell; BMSC = bone marrow stromal cell; BMP = bone morphogenetic 
protein; BNP = BSA-based nanoparticle; CH = chitosan; CM-CH = carboxymethyl chitosan; cRGD = cyclic RGD; DOPA = 3,4-dihydroxyphenylalanine; FB = fibroblast; HA 
= hyaluronic acid; HHC36 peptide = (KRWWKWWRR); MSC = mesenchymal stem cell; NP = nanoparticle; OB = osteoblast; PAA = poly(acrylic acid); PEG = poly(ethylene 
glycol); PEMs = polyelectrolyte multilayers; Phe(4-F) = fluorinated phenylalanine; PLL-g-PEG = poly-L-lysine-graft-poly(ethylene glycol); PMAA = poly(methacrylic acid); SI-
ATRP = surface initiated atom transfer radical polymerization; VEGF = vascular endothelial growth factor; Bacterial strains: Escherichia coli = E. coli; Lactobacillus salivarius 
= L. salivarius; Pseudomonas aeruginosa = P. aeruginosa; Staphylococcus aureus = S. aureus; Staphylococcus epidermidis = S. epidermidis; Streptococcus sanguinis = S. sanguinis; 
Streptococcus mutans = S. mutans.
Table 2. Continued.
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by PLGA and chitosan coatings (Figure 3).[139] Interestingly, the 
polymeric coatings not only improved the drug-release kinetics 
(i.e., decreased burst release) but also enhanced OB-like cell 
adhesion and reduced bacterial viability, representing an ele-
gant example of trifunctional coating (e.g., TNT + antibiotic + 
chitosan). Similarly, the release of an AMP from a TNT-CaP 
coating was tuned using a phospholipid (1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphocholine) capping layer.[160] Regulating the 
delivery of drugs from biomaterials with polymeric coatings 
is not easy and depends on many factors (e.g., the degrada-
bility of the polymer and stability, its chemistry, the number 
of layers deposited, etc.) but opens new avenues to finely con-
trol the antibacterial action, ensuring prolonged effects and 
reducing unspecific toxicity. As new methods become avail-
able, a higher control might be possible. One of such methods 
is plasma polymerization, which has recently shown to be very 
effective in tuning the release of antibiotics from different 
biomaterials.[161,162]
Another approach, not sufficiently explored, would be the 
use of drug delivery systems, i.e., constructs already designed 
to encapsulate and release drugs in a controlled manner. Exam-
ples include micelles, liposomes, and nanoparticles—which 
can moreover be functionalized with signaling molecules to 
improve receptor targeting. While drug delivery carriers func-
tionalized with integrin-binding ligands (e.g., RGD peptides) 
have been widely used to target cancerous cells and specifically 
deliver cytotoxic (anticancer) drugs,[163] immobilization of these 
systems on biomaterials is not common.
In this regard, we recently described the use of RGD-decorated 
polyurethane-polyurea nanoparticles loaded with the antibiotic 
roxithromycin as multifunctional systems to functionalize Ti 
(Figure 4).[164] The multifunctional nanoparticles enhanced OB-
like adhesion (cell numbers, spreading, and focal adhesion forma-
tion) and proliferation compared to plain Ti and Ti functionalized 
with nanoparticles without the RGD motif. Simultaneously, the 
nanoparticles strongly suppressed the adhesion of Streptococcus 
sanguinis on the surfaces in a concentration (i.e., of roxithromycin)-
dependent manner. The nanoparticles released 60–70% of the 
drug within the first 4–6 h, which would address the elevated 
risk of infection postimplantation,[33,165] but the remaining drug 
was released very slowly, allowing a sustained antibacterial effect 
at prolonged periods. Interestingly, the remaining ≈30% of drug 
was still efficient at inhibiting bacterial colonization at longer time 
points. Such design would thus tackle both acute infections post-
surgery and chronic defense mechanisms; however, the applica-
tion of this strategy on biomaterials remains to be fully explored.
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Figure 3. To control the release of gentamicin from TNTs and exert both cell adhesive and antibacterial activity, TNTs were first loaded with gentamicin 
(encapsulated in a micelle polymer nanocarrier, d-α-tocopheryl polyethylene glycol 1000 succinate, TPGS), and then covered by biopolymer coatings 
(polylactic-co-glycolic acid, PLGA, and chitosan). Reproduced with permission.[139] Copyright 2015, Elsevier.
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Bovine serum albumin (BSA)-based nanoparticles (BNPs) 
are also gaining increasing attention as multifunctional sys-
tems with the capacity to control the release of diverse drugs. 
In a recent report, Lu and co-workers described nanostruc-
tured architectures on Ti surfaces by alternating layers of BNPs 
loaded with either BMP-2 or vancomycin.[166] The coatings 
were produced following a layer-by-layer approach, as BNPs 
were coated with chitosan or oxidized alginate to render posi-
tively or negatively charged BNPs, respectively. These coatings 
allowed a long-term sustained release of the drugs and showed 
a remarkable multifunctional potential, while the nanostruc-
tured texture and BMP-2 promoted bone marrow stromal cell 
(BMSC) adhesion, proliferation, and osteogenic differentiation 
(i.e., increased ALP activity), vancomycin inhibited the growth 
of S. epidermidis up to 7 days of incubation (Table 2).[166] These 
systems are versatile and can be used to encapsulate other 
substances. For example, in another study of the same group, 
BNPs-coated with chitosan and loaded with dexamethasone 
were combined with vancomycin-conjugated alginate to pro-
duce films with osteoinductive and antibacterial properties.[167]
3.3. Immobilization of Peptides
The last multifunctional strategy focuses on the covalent immo-
bilization of peptides. This approach, together with the use of 
nanostructured surfaces (see Section 5), is particularly attractive 
to combat infections, as it does not rely on transient drug- 
diffusion processes. Such processes are inherently limited and 
subjected to depletion over time, as well as having the risk of 
promoting antimicrobial resistance.
The coimmobilization of peptides has been widely explored 
to improve the osteoconductive and osteoinductive proper-
ties of biomaterials.[35] This strategy takes advantage of the 
well-defined structure, ease of synthesis, and good stability 
of short peptides, but improves their often moderate to low 
bioactivity and specificity, better recapitulating the complex 
microenvironment of bone ECM. The combination of pep-
tide motifs has proven useful to, e.g., synergize the binding 
toward integrin α5β1 (RGD + PHSRN),[78,79,168] improve 
osteoblast functions via integrin and proteoglycan binding 
(RGD + KRSR/FHRRIKA),[80,169,170] or trigger integrin and 
growth factor signaling (RGD + BMP-derived peptides).[171,172] 
These approaches will not be covered here, but are described in 
detail in the literature.[35,173]
The combination of cell adhesive sequences with AMPs 
offers excellent opportunities to develop multifunctional bioma-
terials. It is important to note that AMPs display high potency 
against a broad spectrum of bacteria. Moreover, the mechanism 
of action of AMPs (i.e., interaction with bacterial membranes) 
appears to have a lower propensity to develop antibacterial resist-
ance compared to conventional antibiotics.[174–177] Following 
this rationale, the functionalization of Ti with an equimolar 
mixture of an RGD peptide and the AMP HHC36 inhibited 
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Figure 4. A) Schematic representation of the multifunctional nanoparticles (NPs). The combination of hydrophilic and hydrophobic moieties confers 
an amphipathic structure to the NP. The drug roxithromycin is encapsulated in the hydrophobic oily core of the NP and the surface is decorated 
with the cyclic RGD peptide c(RGDfK). B) Multifunctional activity of the NPs. C) Immunostaining of OB-like cells on Ti; the samples functionalized 
with RGD-decorated NPs promoted higher cell adhesion and focal adhesions than controls. D) Antibacterial effect of the coatings. Roxithromycin 
significantly inhibits S. sanguinis attachment in a concentration-dependent manner. Ctrol: Ti nonfunctionalized; APTES: Ti aminosilanized; Lys/EDA 
(ethylenediamine): Ti functionalized with NPs (different crosslinker used) without RGD; Lys/EDA-RGD: Ti functionalized with RGD-NPs. Adapted with 
permission.[164] Copyright 2015, Wiley-VCH.
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the attachment of S. aureus and E. coli while improving BMSC 
adhesion.[178] Although the authors implemented a click 
chemistry-based methodology to modify the proportion of pep-
tide grafting, controlling the concentration, ratio, and spatial 
organization of peptide mixtures upon binding to a surface is 
a challenging task and not always possible. To address that, 
we developed a peptidic branched platform with the capacity 
to simultaneously present two peptide sequences in a chemi-
cally controlled fashion.[78,79] Using this platform we recently 
combined the RGD sequence with LF1-11, an AMP derived 
from lactoferrin that showed excellent antibacterial properties 
on Ti surfaces.[179,180] Such approach very effectively improved 
OB adhesion, proliferation, and mineralization, and inhibited 
S. aureus and S. sanguinis attachment and biofilm progression 
(Figure 5).[181] Importantly, the bifunctional molecule was also 
effective in a coculture scenario in which the surfaces were 
exposed to bacterial suspensions (preinfective condition) for 2 h 
before seeding OB-like cells. On nonfunctionalized surfaces, 
the presence of bacteria drastically inhibited cell attachment. 
By contrast, on the surfaces coated with the RGD/LF1-11 plat-
form, normal cell adhesion and viability was preserved. Scanning 
electron microscopy (SEM) analysis further revealed that in 
such a competitive scenario, bacteria directly interfered with 
OBs (e.g., by surrounding and covering them), preventing 
eukaryotic cells from attaching and adequately spreading. The 
multifunctional coating, through its dual cell adhesive and 
antibacterial effect, proved useful to overcome the deleterious 
effects of initial bacterial adherence. These data support the 
concept of the “race for the surface”[14,38] and indicates that 
rather than a competition cells actually “fight for the surface.”
Although this strategy has potential to develop anti-infective 
coatings, it should be emphasized that surviving bacteria, 
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Figure 5. A) Classical approaches tend to functionalize surfaces with either cell adhesive or antibacterial peptides, but ignore a combined effect. Using 
a peptidic platform both activities can be simultaneously exploited on the biomaterial surface. B) Chemical structure of the multifunctional platform. 
C) Immunostaining of actin fibers on cell–bacteria coculture studies. Preincubation of Ti surfaces with bacteria (S. sanguinis or S. aureus) inhibits the 
adhesion of OB-like cells (upper row); functionalizing the surfaces with the platform restores cell adhesion to normal levels (lower row). D) SEM 
analysis of OB-bacteria interactions. In the absence of the platform bacteria surround cells and block their spreading. SS: S. sanguinis; SA: S. aureus. 
Adapted with permission.[181] Copyright 2017, American Chemical Society.
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even very low numbers, might be capable of proliferating on 
the implant surfaces, initiating the formation of new biofilms. 
Moreover, bacterial debris and proteins from the extracellular 
environment may serve as new anchoring points for other colo-
nizers.[182] To solve this, cell adhesive and antibacterial peptides 
can be combined together with antiadhesive polymer coatings 
to confer biomaterials with a trifunctional potential (cell adhe-
sive, bacterial repellent/bacteriostatic, and bactericidal). We 
recently followed this approach (Figure 6), combining PEG coat-
ings electrodeposited onto Ti surfaces with the aforementioned 
RGD/LF1-11 platform, which was covalently attached to the PEG 
layers using a maleimide cross-linker.[183] As expected, PEG coat-
ings inhibited protein adsorption and cell (both bacteria and OB-
like cells) adhesion. However, the presence of the RGD sequence 
efficiently rescued cell adhesion, while the AMP increased 
the antibacterial potential of the coatings, reaching values of 
S. sanguinis adhesion below 0.2% (Table 2 and Figure 6). In 
another example, the triblock copolymer Pluronic F127 (PEG–
polypropylene glycol–PEG) (PF127) was functionalized with 
either RGD or an AMP to coat the biomaterial surfaces.[184] In 
detail, surfaces were coated with different mixtures of PF127, 
PF127-RGD, and PF127-AMP. By tuning the proportion of these 
polymers, antibacterial potential against S. aureus, S. epidermidis, 
and P. aeruginosa, or improved FB adhesion could be obtained.
An alternative approach would be the combination of AMPs 
with GFs. In this regard, Yüksel et al. recently described a 
bilayer of PLGA membranes with antibacte-
rial and bioactive properties.[185] The dual 
function was achieved by covalently immobi-
lizing the AMP magainin II within one of the 
layers, and incorporating epidermal growth 
factor (EGF) in the other layer. This approach 
reduced the adhesion of E. coli and S. aureus 
and supported FB adhesion. This strategy 
opens the way to combine AMPs with other 
GFs (e.g., BMPs) or osteogenic peptides. 
Particularly interesting would be the coim-
mobilization of AMPs with BMP-derived pep-
tides,[186,187] as this strategy would allow for 
an osteogenic effect at the implantation site, 
reducing the risk of an uncontrolled release 
of GFs. However, while RGD has been 
coimmobilized with peptides derived from 
BMP-2[171] or BMP-7,[172] showing enhanced 
osteogenic differentiation of stem cells, the 
combination of BMP-mimetics with AMPs 
remains to be explored. Another approach 
that deserves further investigation is to inte-
grate dual functions within one single bio-
molecule. Bronk et al. engineered a collagen-
mimetic molecule that upon immobilization 
on Ti enhanced OB-like cell adhesion and 
differentiation, and prevented S. aureus and 
S. epidermidis colonization.[188] Godoy-
Gallardo et al. reported a simple but effective 
multifunctional strategy by grafting triethox-
ysilypropyl succinic anhydride (TESPSA) on 
Ti. Silanes have been widely used as cross-
linker to attach bioactive peptide sequences; 
however, in this study, the silane alone enhanced the expression 
of osteogenic markers on OB-like cells, decreased the adhe-
sion of S. sanguinis and Lactobacillus salivarius, and supported 
FB adhesion in a coculture competitive setting in the presence 
of bacteria.[189] Yuran et al. recently reported a minimalistic 
bifunctional peptide combining the RGD sequence with two 
units of fluorinated phenylalanine (Phe(4-F)), which promoted 
peptide self-assembly into cell adhesive and bacterial resistant 
coatings.[190] The amino acid 3,4-dihydroxyphenylalanine 
(DOPA) was used as anchoring unit to bind the peptide to Ti 
surfaces (Table 2).
4. Osteogenic Nanotopographies
We have already discussed that implant osteointegration can 
be enhanced by physical and chemical methods. While phys-
ical modifications (i.e., surface roughness) improve implant 
functionality by increasing its micromechanical retention 
with bone, chemical coatings such as integrin-binding mole-
cules or CaP have been described to promote osteogenesis 
from mesenchymal stem cells (MSCs). While roughness is 
undoubtedly useful, it is hard to dissect effects as surfaces with 
two similar Ra values can appear very different and so could 
potentially have different effects on cells. This section of the 
review will focus on cell response to defined nanotopography 
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Figure 6. A) Trifunctional strategy: i) a repellent coating (e.g., PEG) prevents bacterial attach-
ment; ii) a cell adhesive sequence (e.g., RGD) supports eukaryotic cell adhesion; and iii) a bac-
tericidal molecule (e.g., AMP) kills adhering bacteria. B) Combining the low fouling potential 
of PEG with a cell adhesive/bactericidal platform (RGD + LF1-11) efficiently supports OB-like 
cell adhesion but totally suppresses the adhesion of S. sanguinis. (6B) Reproduced with permis-
sion.[183] Copyright 2018, Elsevier.
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with particular consideration on nanotopographically directed 
osteogenesis. We note that roughness based approaches are 
being developed—most notably for orthopedic application (see 
Section 2.1). These are not a focus of this review, but excellent 
reviews are available.[191,192]
The ability of surface topography to guide cells has been 
known for over 100 years,[193] with the term “contact guidance” 
becoming used in the 1950/1960s.[194,195] In the 1980s, under-
standing of the cell–topographical interaction at the microscale 
started to become elucidated thanks to microfabrication tech-
niques such as photolithography and wet/dry etch.[196,197] This 
proliferation of biological data revealed that all cell types tested 
responded to microtopographical features.[198–204] As semicon-
ductor technology advanced to help develop faster computer 
microchips, the study of nanotopographical–cell interactions 
became possible with first indications of the cells’ ability to 
contact guide to nanopatterns shown using substrates derived 
from laser holographical lithography.[205] By the turn of the 
21st century, both top-down (lithographical, e.g., electron 
beam lithography, colloidal lithography[206–208]) and bottom up 
(e.g., polymer phase separation, block copolymer separation, 
etc.[209–212]) approaches were becoming available to cell biolo-
gists. These substrates allowed development of understanding 
that cells could respond to features where all features were 
nanoscale;[213] soon it was understood that a broad range of cells 
could respond to nanoscale features[214]—even platelets.[215]
Considering controlled topography, top-down techniques 
such as electron beam lithography (EBL) allow patterning for 
cell experimentation with features down to 10 nm in size.[216] 
Moving from cell-scale to clinical-scale may, however, be chal-
lenging for such techniques.
By contrast, bottom-up techniques such as polymer phase 
separation,[210] colloidal lithography,[217] block copolymer lithog-
raphy,[218] and micelle lithography[219] where larger areas can 
be fabricated more simply—but with some loss of the resolu-
tion that EBL can offer—are gaining popularity. However, for 
bone formation perhaps this is not so important. A study using 
EBL to fabricate nanopits with 120 nm diameter, 100 nm depth, 
and 300 nm center-to-center positioning in a square pattern 
showed that MSCs did not form osteoblasts when the features 
were precisely placed (in fact a later study showed enhanced 
MSC self-renewal[220])—rather osteoblast specific differentia-
tion was only observed when the features were slightly offset 
(by up to ±50 nm from the center positioning) (Figure 7A).[221] 
It is thus noteworthy that block copolymer micelles can now 
be fabricated almost to the scale that EBL has been used to 
generate controlled nanodisorder, i.e., with ±50 nm feature off-
sets known to drive cell function.[222] Copies (via nickel shims) 
of phase separated nanosurfaces and colloidal nanosurfaces in 
biopolymers (polymethylmethacrylate and polycaprolactone) 
have now been shown to influence MSC growth in vitro.[223] 
Further, such bottom-up methodologies have been used to gen-
erate masks for anodization of, e.g., Ti implant materials to 
enhance osteogenesis.[224–227]
Moving into 3D is challenging for lithographical and 
demixing processes due to their 2D natures. Interestingly for 
tissue engineering, polymer demixing can be performed inside 
3D constructs such as tubes[228] and, indeed, influence MSC 
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Figure 7. Nanoscale topographical control of MSC differentiation. A) MSCs respond to nanoscale disorder. Using electron beam lithography to 
fabricate arrays of nanopits (120 nm diameter, 100 nm deep) in a square array (SQ, 300 nm center–center pitch) with up to ± 50 nm offset from the 
center square position (nano), increased adhesion and adhesion colocalization of integrin (here integrin beta 5 is stained) and the BMP2 receptor 
(here BMPR1a is stained) and this drives MSC osteogenic progression, as demonstrated by expression patterns of the osteogenic genes RUNX2 
(runt related transcription factor 2), osterix (OSX), osteopontin (OPN), osteocalcin (OCN), and alkaline phosphatase (ALP). Adapted with permission 
under the terms of the Creative Commons Attribution 4.0 International license (CC BY 4.0).[237] Copyright 2014, the Authors. Published by American 
Chemical Society. B) Synthetic collagen banding patterns with 100 nm repeat (nonphysiological) and 63 nm repeat (physiological); MSCs are stimulated 
to undergo osteogenesis on the physiological pattern, but not the nonphysiological pattern. Adapted with permission.[235] Copyright 2013, American 
Chemical Society.
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growth.[229] Tube-like structures are typical in bone, e.g., Haver-
sian and Volkman’s canals (the osteon system). A further major 
development toward 3D is a topographical approach with the 
potential to incorporate ultraprecise (e.g., lithographical) nano-
topographical fabrication.[230] In this system, a biodegradable 
polymer (e.g., polycaprolactone) was embossed between two 
micrometers or nanopatterned surfaces. Included in the design 
were spacing posts (≈50 µm high) to allow perfusion of media 
and oxygen during preconditioning. The embossed sheet was 
rolled to form a larger construct and seeded with cells prior to 
preconditioning in vitro. Also, “car-park” assemblies have been 
made using osteogenic micropatterns embossed onto poly-
meric sheets that incorporate large spacers to separate layers of 
the “car-park;”[231] embossing of osteogenic nanotopographies 
in this system is easily envisaged.
If we consider mechanism of cellular response, cell adhe-
sions are very sensitive to nanoscale features, being able to 
form filopodia in response to topographies down to 10 nm in 
height[232] but, further, being seen to have “nanopodial” inter-
actions down to 8 nm in height.[233] At the microscale, contact 
guidance by features of similar scale to the cells themselves is 
easy to envisage (i.e., they have no choice). At the nanoscale, 
however, subcellular features, i.e., adhesions, must reorganize 
to guide cells. As adhesive proteins encounter a nanoscale cue 
(e.g., a nanogroove or a fibronectin line)—an order of magni-
tude smaller than the cell, but on a similar scale to filopodia 
and integrin receptors—the adhesions will elongate along the 
cue and this, in turn, will drive actin alignment in the direction 
of the cues.[234] This will align the cell literally, and metaphori-
cally, from the bottom-up (in fact, this is a first step for large 
scale tissue organization during development).
In the context of this review, particularly studied has been 
MSC to osteoblast (bone forming progeny) differentiation. 
A range of nanoscale topographies from nanodisordered sur-
faces[221] to biomimetic helical structures with collagen-like 
63 nm periodicity[235] have been demonstrated to induce osteo-
genesis (Figure 7B).
At the cell–material interface, cell adhesion formation has 
been widely studied and is considered important in defining 
MSC to osteoblast differentiation. When observing MSC differ-
entiation to bone, it is not the number of adhesions that a cell 
can form per se that is important for bone production, rather 
the size of the adhesions. Studying MSC adhesion size during 
osteogenesis shows that larger adhesions form.[221] In addition, 
it has been shown using RGD functionalized gold nanopat-
terns that a slight disorder significantly enhances MSC adhe-
sion.[219] It has been seen that disorder can increase adhesion 
through bringing groups of adhesive points closer together, 
into a critical 70 nm range[236] to facilitate gathering of integrins 
into focal adhesions. Also, MSCs cultured on osteogenic nano-
patterns have been indicated to express endogenous vitronectin 
over fibronectin.[237] Vitronectin may be important, as it allows 
better bridging between integrin clusters via intracellular adhe-
sion proteins such as vinculin and talin.[238] Efficient bridging 
will allow cells to form larger, more mature adhesions, over dis-
continuities such as nanopits.
In further consideration of adhesion mechanism, the 
forma tion of “super-mature” adhesions[239] (>5 µm long) is 
important for stabilizing the large osteoblast morphology 
and resultant bone formation. It is likely that such super-
mature adhesions are stabilized/scaffolded by proteins such 
as RACK1,[240,241] allowing increased levels of intracellular ten-
sion,[242,243] mediated by RhoA Kinase (ROCK), important to 
MSC fate.[244–246]
5. Antimicrobial Nanotopographies
We have seen in the previous sections that current strategies 
to combat biomaterials-associated infections are largely reliant 
upon chemical means, i.e., use of polymers (or surface func-
tional groups) to prevent protein adsorption and inhibit bacterial 
adhesion, or coatings that release chemical agents such as 
antibiotics, silver ions, or quaternary ammonium salts into the 
surrounding microenvironment. A critical limitation of these 
chemistry-based strategies is that they are transient because 
leaching of antimicrobial agents is limited and subject to 
depletion over time. Dwindling antibiotic concentration and/
or prolonged bacterial colonization of materials may also inad-
vertently promote development and spread of antimicrobial 
resistance. A physical approach, such as topography, could 
potentially overcome the above problems and offers completely 
new and alternative solutions to biomaterial infections.
5.1. Anti-Biofouling Nanotopographies
Surface topography has been known to alter bacterial adhe-
sion and biofilm formation. It has become evident that surface 
hydrophobicity/hydrophilicity and effective contact area are 
two key factors that are responsible for the different bacterial 
adhesive behavior on surfaces. A well-known example is the 
superhydrophobic “lotus effect,” which is the result of a com-
bination of hydrophobic chemistry (wax) and the hierarchical 
and multiscale surface structure, i.e., nanostructures on micro-
structures. The hydrophobic epicuticle layer, with high density 
of nanofeatured wax crystalloids, covers microfeatured convex 
surface structures, creating a surface with very high contact 
angle (≈161°).[247] It was found that when the surface of a lotus 
leaf was dipped in ethanol to remove the wax, the contact angle 
of a water drop decreased dramatically from ≈161° to 122°, and 
the water droplet was pinned to the surface.[248] This intrinsic 
hydrophobicity of the surface principally originated from the 
pure hierarchy of multiscale structures, similar to that observed 
on the surface of a rose petal. The lotus effect requires air to 
become “trapped” between the nanostructures on the surface, 
i.e., the Cassie and Baxter state, while the rose petal effect allows 
the liquid film to impregnate the micro/nano topographies, i.e., 
the Wenzel state, because the nonwaxy petal surface has good 
wetting characteristics with water. Many plant leave surfaces 
with micro/nanotopographies, e.g., rice and taro, have been 
shown to be able to control the bacterial fouling and biofilm 
formation.[249,250] Inspired by nature, various nanoengineered 
surfaces have been investigated in terms of their surface hydro-
phobicity/hydrophilicity and nanotopography. Hizal et al.[251] 
reported two nanostructured superhydrophobic surfaces with 
extremely low bacterial adhesion under dynamic flow condi-
tion. Both 2D nanoporous surface and 3D nanopillared surface 
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showed a significant reduction in adhesion for S. aureus and 
E. coli, which was more pronounced for the hydrophobic surface 
treated with a Teflon coating (Figure 8). This was attributed to a 
decreased contact area for the 2D porous surface and effective 
air entrapment in 3D nanopillars. The bacterial adhesion force 
on these nanoengineered surfaces was reduced as measured 
by atomic force microscopy. Similar antifouling effects were 
observed on hydrophilic TiO2 nanopillars[252] or nanotubes.[253] 
The nanofeature dimensions, e.g., nanopillar diameter, 
height, and spacing affected the bacterial adhesion due to the 
change of effective contact area.[254,255] Strong bacterial repel-
ling has also been reported on highly ordered alumina nano-
porous surfaces[256] and polymer (PLGA) nanopit surfaces 
with pore sizes ranging from 200 to 500 nm.[257] This contact- 
area-reducing approach has been attempted in real medical 
applications. Serrano et al.[258] reported oxygen plasma treated 
sutures with lamellae voids with feature size ≤ bacteria size. 
The results showed that bacterial attachment was decreased 
with reduced surface contact area and effective prevention 
of biofilm formation was achieved in absorbable sutures 
with top area fractions below 30% presenting lamellae with 
200–500 nm thickness and several micrometers in length, 
separated by 1–2 µm voids.
5.2. Bactericidal Nanotopographies
Bactericidal nanotopographies have not been reported until 
recently, although bactericidal nanostructures in the form 
of suspended colloids were investigated much earlier. For 
example, Liu et al. reported that single-walled carbon nano-
tubes (SWCNTs) in a suspension are bactericidal upon contact 
with bacteria. They found that the sharpness and concentration 
of the SWCNTs coupled to mechanical shaking of the SWCNT 
suspension could enhance the bacteria-killing performance. 
They described these SWCNTS as “nano darts” which were able 
to physically pierce the bacterial cells.[259]
Ivanova et al. first reported bactericidal nanotopogra-
phies on cicada (Psaltoda claripennis) wings. When culturing 
P. aeruginosa cells on Psaltoda claripennis wings, which com-
prised 200 nm tall nanopillars (or nanocones) with a diameter 
of 100 nm at the base and 60 nm at the cap, and spaced 170 nm 
apart from center to center, it was noted that the bacterium 
died.[260] They postulated that cell death was caused purely by 
the mechanical rupturing of bacterial cell walls. A biophysical 
model has been developed to explain the mechanobactericidal 
action of the cicada wings.[261] Kelleher et al. tested three dif-
ferent cicada wings (Megapomponia intermedia, Ayuthia spect-
abile, and Cryptotympana aguila).[262] They found a strong cor-
relation between the bactericidal properties of the wings and 
the scale of the nanotopographies present on the different wing 
surfaces. Sharper and more densely packed nanopillars on 
Megapomponia intermedia wings killed more bacteria, prob-
ably by inducing a greater strain on the bacterial cell walls. Sub-
sequently, more naturally occurring bactericidal surfaces have 
been reported.[263,264] They include nanopillars on the dragonfly 
wing,[265] the damselfly wing,[266] the moth eye,[267] the rat-tailed 
maggot, the aquatic larva of the Drone fly,[268] and the nano-
tipped hairs on gecko skin.[269]
Inspired by nature, a number of studies have since been car-
ried out to develop bactericidal nanotopographies on synthetic 
materials. They include silicon[270–273] and diamond coated 
silicon,[274–276] titanium and its alloy,[277–283] polymers,[284–287] 
stainless steel,[288] and aluminium.[289] Table 3 lists a summary 
of biomimetic bactericidal surfaces on various materials cur-
rently in development. Examples of some bactericidal nano-
topographies created on various synthetic materials are shown 
in Figure 9.
Ivanova et al. first reported the studies of biomimetic bacte-
ricidal surfaces on synthetic materials in 2013,[270] shortly after 
their discovery of bactericidal cicada wings in 2012.[260] Nano-
protruding surfaces with high-aspect-ratio nanopillars with a 
diameter of 20–80 nm and a height of 500 nm were generated 
on silicon substrates using a reactive ion etching (RIE) method, 
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Figure 8. A–D) Field emission (FE)-SEM images and E–H) schematics representing the bacterial adhesion on hydrophobic nanopillared surfaces. In 
panels (E) and (G), the schematics represent the bacteria are floating over the entrapped air layer under static conditions. In panels (F) and (H), the 
schematics represent the bacteria being washed off under flow. Reproduced with permission.[251] Copyright 2017, American Chemical Society.
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creating “black silicon” (bSi), which mimics the wings of the 
dragonfly Diplacodes bipunctata. Notably, the bSi surfaces 
exhibited bactericidal activity toward both Gram-positive and 
Gram-negative bacteria. Of note too, the range and bactericidal 
efficacy were larger than their biological analogues (cicada and 
dragonfly wings). Further study indicated that the bactericidal 
efficacy was strongly dependent on their feature sizes. Smaller 
and more densely packed pillars exhibited the greatest bacteri-
cidal activity.[272] The decrease in the nanopillar heights, nano-
pillar cap diameter and inter-nanopillar spacing corresponded 
to a subsequent decrease in the number of attached cells for 
both Gram-positive and Gram-negative bacterial species.[272]
Adv. Healthcare Mater. 2019, 8, 1801103
Figure 9. Examples of various synthetic bactericidal nanotopographies on different substrates. A) Black silicon (bSi). Reproduced with permission.[270] 
Copyright 2013, Springer Nature. B) Diamond coated bSi. Reproduced with permission.[275] Copyright 2016, The Royal Society of Chemistry. C) A 
pierced bacterium on bSi. Reproduced with permission.[276] Copyright 2018, The Royal Society of Chemistry. D) Diamond nanocones. Reproduced 
with permission.[274] Copyright 2016, American Vacuum Society. E) Hydrothermal TiO2 nanowires.[277,279] Reproduced with permission under the terms 
of the Creative Commons Attribution 4.0 International license (CC BY 4.0).[279] Copyright 2018, the Authors. Published by Springer Nature. F) TiO2 
nanowires by thermal oxidation. Reproduced with permission.[283] Copyright 2016, Elsevier. G) Black titanium (bTi). Reproduced under the terms of 
the Creative Commons Attribution 4.0 International license (CC BY 4.0).[282] Copyright 2017, Springer Nature. H) PMMA nanocones. Reproduced with 
permission.[284] Copyright 2015, American Vacuum Society.
Table 3. Current development in biomimetic and bioinspired bactericidal surfaces on various substrates.
Material Surface nanotopography Fabrication method Bacteria studied Ref
Silicon Nanopillars
Nanoneedles
Nanowires
Reactive ion etching (RIE), 
metal-assisted chemical etching
P. aeruginosa, S. aureus, and Bacillus subtilis [270–273]
Diamond and diamond coated Si Nanocones Chemical vapor deposition 
(CVD) + bias assisted RIE
P. aeruginosa [274]
Nanoneedles RIE + CVD P. aeruginosa, E. coli, and Streptococcus gordonii [275,276]
Titanium Nanowires Hydrothermal growth S. aureus, S. epidermidis, P. aeruginosa, E. coli, B. subtilis, 
Enterococcus faecalis, and Klebsiella pneumoniae
[277–280]
Nanocolumns Glancing angle sputter 
deposition
E. coli and S. aureus [281]
Nanopillars RIE E. coli, P. aeruginosa, S. aureus, and M. smegmatis [282]
Ti alloy Nanocones
Nanowire
Thermal oxidation E. coli [283]
Polymers Nanopillars
Nanocones
Nanoimprinting E. coli, P. aeruginosa, and S. Aureus [284–286]
Nanopillars
Nanocones
Colloidal lithography E. coli and K. pneumoniae [287]
Stainless steel Nanoprotruding 
textures
Electrochemical etching E. coli and S. aureus [288]
Aluminium Micro/nanorough 
surfaces
Chemical etching E. coli, K. pneumoniae, and S. aureus [289]
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Similar nanopillar and nanowire surfaces using dif-
ferent etching methods also displayed similar bactericidal 
activity.[271–273] Susarrey-Arce et al. investigated the interaction 
and the viability of bacteria on highly oriented silicon nanowires 
(SiNWs) with and without functionalization. They found that the 
bare SiNWs and SiNWs functionalized with a silane (APTES) 
exhibited some degree of intrinsic bactericidal activity toward 
E. coli and S. aureus. However, bacterial cells could still prolif-
erate for a long time on these topographic surfaces. By function-
alization with chlorhexidine digluconate (CHD), the antimicro-
bial performance was greatly enhanced because CHD released 
from the surface had the potential to decrease the viability of 
both sessile and planktonic bacterial cells. They have also identi-
fied two different growth modes producing distinct in-plane and 
out-of-plane bacterial colonies for E. coli and S. aureus, respec-
tively.[273] However, silicon is a nonload-bearing material and 
thus has limited application in biomedical implants.
Diamond coating using thin film technology is becoming 
an attractive approach for material functionalization for bio-
medical applications due to its unique properties. It is bioinert 
and its electrical conductivity can be tuned from insulating to 
near-metallic, which makes it a potential candidate material 
for orthopedic and neural device applications.[290] Fisher et al. 
demonstrated that diamond nanocone arrays deposited on a 
silicon substrate via microwave plasma chemical vapor depo-
sition (CVD) followed by bias-assisted RIE were bactericidal 
toward P. aeruginosa.[274] Similar antimicrobial performance has 
also been reported for diamond coated bSi nanoneedles.[275,276] 
Interestingly, such a diamond coating or film could be depos-
ited on Ti substrates, which may have important medical impli-
cations, as Ti metal and its alloys are widely used materials in 
orthopedic, dental, and cardiovascular applications.
Because of the wide applications of Ti in biomedicine and 
the frequent biomaterials associated infections, the generation 
of antimicrobial nanosurfaces directly on Ti substrates would 
be desirable. Inspired by the cicada wings, Diu et al. first inves-
tigated bactericidal property and biocompatibility of nanowires 
grown directly on Ti substrates using an alkaline hydrothermal 
method.[277] It was found that motile and Gram-negative bac-
teria are more susceptible to killing than nonmotile and 
Gram-positive ones. Culturing in dynamic (shaking) conditions 
also induced more killing compared to standard static bacterial 
cell culture condition. It is suggested that the thicker cell wall 
(peptidoglycan layer) found in Gram-positive cells and a lack of 
motility in nonmotile cells may be responsible for their inferior 
susceptibility to killing.
Similar works have reported on hydrothermal nanowires with 
various bactericidal performances depending on processing 
and culturing conditions.[278–280] Cao et al. investigated longer-
term biofilm formation of S. epidermidis on spear or brush-type 
and pocket or niche-type nanowires. Pocket-type nanowire sur-
faces were found to delay biofilm formation up to 6 days and 
exhibited more recalcitrance toward S. epidermidis biofilm for-
mation. It was believed that microsized pockets formed by the 
intertwined nanowires may result in the entrapment of bacte-
rial cells which prevented their crosstalk and proliferation.[279] 
The advantage of hydrothermal treatments is that they can be 
easily applied to porous Ti substrates.[291] Nanoflowers, rods, 
and wires were formed in porous Ti alloy scaffolds using an 
aqueous mixture of calcium hydroxide [Ca(OH)2] and sodium 
tripolyphosphate depending on their ratios and hydrothermal 
conditions. Nanowire surfaces exhibited bactericidal proper-
ties against S. aureus and E. coli as well as osteogenesis from 
bone cells. Similarly, nanowire surfaces were generated on Ti 
alloy substrates using a controlled thermal oxidation method, 
which also showed bactericidal[283] and osteogenic[292] proper-
ties. Crucially, this method could be applied to porous and com-
plex shaped Ti substrates, which paves the way to develop cell-
instructive nanotopographies for implant applications.
Other fabrication methods have been investigated to pro-
duce nanostructured surfaces on Ti substrates. Sengstock 
et al. reported Ti nanocolumnar structures produced using a 
glancing angle sputter deposition (GLAD) technique. It was 
again observed that there was more killing of Gram-nega-
tive rod-shaped E. coli than the Gram-positive sphere-shaped 
S. aureus. Apart from their cell wall differences discussed 
before, their different cell viability on the nanocolumnar 
structures may also be resulted from their difference in the 
structural process of cell division. Rod-shaped E. coli bacteria 
multiply by elongating which requires an in-plane movement 
of the cell body attached to the nanostructures, by which the 
friction forces during cell dividing dynamics may lead to the 
damage or disruption of cell wall. By contrast, cell divisions of 
sphere-shaped S. aureus occur in three dimensions, with the 
daughter cells remaining nearby leading to grape-like clus-
ters or out-of-plane growth, which resulted in fewer daughter 
cells in direct contact with the nanocolumnar surface during 
cell division process, therefore causing less damage to the cell 
wall by the friction force.[281] Analogous to black silicon, Hasan 
et al. reported the generation of Ti nanopillars or black Ti (bTi) 
using a chlorine based RIE technique. Within 4 h of contact 
with the bTi surface, 95% ± 5% of E. coli, 98% ± 2% of P. aerugi-
nosa, 92% ± 5% of Mycobacterium smegmatis, and 22% ± 8% of 
S. aureus cells that had attached were killed. The killing effi-
ciency for the S. aureus increased to 76% ± 4% when the bacte-
rial cells were allowed to adhere up to 24 h.[282]
Polymers are also widely used in medical devices such as 
catheters, feeding tubes, contact lenses, dental prostheses, and 
orthopedic implants. Nanopatterned surfaces can be fabricated 
using nanoimprinting and colloidal lithography, both are line-
of-sight 2D processes. Dickson et al. found that nanopillars 
replicated from imprinting of lithographically produced moulds 
and cicada wings were bactericidal against E. coli. Sharper, 
more closely packed nanopillars were more effective, pos-
sibly because bacteria on these surfaces both contacted more 
nanopillars and experienced higher stresses at these contact 
points,[284] which was in agreement with that found in different 
insect species.[262] Replication of moth eye-like nanopillars/
cones via nanoimprinting also demonstrated good bactericidal 
performance in both dry and wet conditions,[285,286] which could 
potentially be used for inhibiting nosocomial infections or any 
sanitation-conscious touching surfaces. Hazzel et al. produced 
similar nanopillar/cone surfaces using colloidal microbeads as 
masks followed by RIE. It was shown again that surfaces with 
the most densely packed nanopillar/cone arrays (center-to-
center spacing of 200 nm), higher aspect ratios (<3), and sharp 
tip widths (>20 nm) killed the highest percentage of bacteria 
(≈30%).[287]
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It is worth noting that the exact mechanisms of bacteria-
killing by nanostructures are still not completely clear. One of 
the most-widely accepted mechanisms is the physical defor-
mation or rupturing of bacterial cell wall/membrane by sharp 
nanopillars.[261] However, other mechanisms cannot be ruled 
out, depending on the nanofeature size and structural process 
of bacterial cell division. For example, the physical entrap-
ment of bacteria within nanopillars or nanowires may impede 
the proliferation and growth of bacteria.[279] The friction forces 
exerted on the Gram-negative bacterial cell wall during their 
division process may also result in the damage of bacterial cell 
wall.[281] It is therefore important to elucidate the nanotopog-
raphy-induced antibacterial mechanisms in order to rationally 
design and fabricate nanostructures for relevant biomedical 
applications.
6. Cell-Instructive (Osteogenic and Antibacterial) 
Nanotopographies
For many biomedical applications, surfaces with cell-instructive 
or cell-selective functionalities that are able to control the fate 
of both mammalian and bacterial cells at the same time are 
highly desirable. As previously discussed, orthopaedic implants 
provide a good example of a sector requiring cell-instructive 
surfaces that could simultaneously promote osseointegration 
and prevent bacterial infection. This is because the increased 
demand for orthopaedic prosthesis is fueled by both aseptic 
loosening (due to poor osseointegration) or infection (due to 
bacterial infiltration and biofilm formation).[10,293]
The use of topographical cues to selectively modulate cells 
and bacteria has becoming increasingly reported mostly on 
pure Ti metal and its alloys (e.g., Ti6Al4V) because they are 
most widely used materials for endosseous implants. For 
example, Peng et al. reported that concave nanotopographies, 
e.g., TiO2 nanotube arrays with diameters of 30–80 nm grown 
on Ti substrates via anodization exhibited reduced adhesion 
and lower colonization of bacterial cells (S. epidermidis) but 
enhanced, increased, adhesion of osteogenic cells.[143] Similar 
cell-selective behavior was observed on nanoporous surfaces 
for human gingival FBs and oral bacteria (S. mutans, Fusobac-
terium nucleatum, and Porphyromonas gingivalis).[294] Different 
cell-selective behavior has also been reported on convex nano-
topographies. Densely packed Ti nanocolumns with diameters 
of 40–60 nm fabricated via GLAD showed strongly reduced 
bacterial (S. aureus) adhesion and biofilm formation, while 
osteoblast cells grew well on such surfaces. The selective cell 
behaviors were attributed to the “lotus leaf effect” caused by the 
nanocolumnar arrays and the difference in the dimensions of 
osteoblast and bacterial cells.[144]
Since the recent discovery of high aspect ratio bactericidal 
nanotopographies as reviewed in Section 5, research has been 
carried out on selective cellular responses of both mammalian 
cells (OBs, MSCs, and other cells) and bacteria to such surfaces. 
Ivanova and co-workers demonstrated, for example, that while 
bSi surfaces killed bacteria, the COS-7 eukaryotic cell model 
could survive and grow.[295] In fact, the bactericidal nanotopog-
raphies, fabricated from bSi with densely packed nanoneedles, 
promoted the growth and proliferation of fibroblastic cells. 
Such nanotopography was not only biocompatible but also 
reduced inflammatory response in a mice model compared 
with the flat controls.[295] For orthopaedic application, however, 
we need to consider bone forming cells. Diu et al. noted that 
the metabolic activity of OB (MG63) cells cultured on bacteri-
cidal hydrothermal TiO2 nanowire surfaces was only slightly 
decreased after 14 days of cell culture and that while prolifera-
tion of OB cells was slowed, especially on long TiO2 nanowires 
that formed secondary “pocket” structures, the cells did grow 
with time. A noticeable change in cell morphology was that 
some cells became elongated due to “pinning” of osteoblast 
cells on bactericidal TiO2 nanowire arrays.[277] Similar results 
were reported from other groups using different materials or 
other cell lines.[278,280,282]
Most interestingly, these convex high-aspect-ratio bactericidal 
nanotopographies seem capable of directing the differentiation 
of MSCs into OBs, which could have positive implication to the 
real-world applications in orthopaedic or dental implants where 
both antimicrobial and osseointegrative properties are vital to 
ensure their long-term success. Tsimbouri et al. investigated 
osteogenesis of bactericidal TiO2 nanowires using a mesen-
chymal BMSC/bone marrow hematopoietic cell coculture model 
where both osteogenesis and osteoclastogenesis can occur.[296]
Similar to the previous results,[277] BMSCs were well-spread 
on shorter “fine” or “brush” nanowire surfaces (2 h of anodi-
zation) with well-organized cytoskeleton but grew slightly less 
well compared with the polished control. Nevertheless, cell 
proliferation was impaired when growing on longer “coarse” 
or “niche” nanowire surfaces (>2 h) (Figure 10). Cells tended 
to “trap” inside the pockets formed by the intertwined nanow-
ires. Interestingly, analysis of osteogenic markers osteopontin 
and osteocalcin at the transcript and protein level demonstrated 
an increase in osteogenesis on the 2 h nanowire surface com-
pared with the polished control. This indicated that such a 
surface could be both bactericidal and osteogenic, thus poten-
tially useful in the development of cell-instructive implants. It 
is notable that the nanowires also prevented osteoclastogenesis 
and this could have implication in reducing osteolysis.
7. The Synergy of Nanotopography  
and Chemical Coatings
Nanotopographies with bactericidal potential and capacity to 
support bone cells populations would be ideal substrates for 
developing new medical implants, and the recent literature 
indicates this is possible (see previous section). However, it 
is difficult to design cell instructive surfaces with topography 
alone, i.e., there is typically a reduction in spreading and/or 
proliferation of bone-related cell types on high aspect ratio bac-
tericidal topographies compared to control Ti surfaces.[277,282,296] 
A potential solution to achieve this would be the functionaliza-
tion of such high aspect-ratio nanotopographies with che-
mical ligands with integrin-binding potential. As discussed in 
Section 4, it is important for bone forming cells to form “super-
mature” focal adhesions (>5 µm long) in order to stabilize the 
large OB morphology and thus promote osteogenesis. Thus, a 
combined topography-chemistry approach could improve cell 
function on less adherent surfaces.
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Fraioli et al. further investigated the use 
of peptidic ligands combined with bacte-
ricidal TiO2 nanotopographies to improve 
integrin-specific cell adhesion and hopefully 
enhance osteogenesis (Figure 11).[297] It was 
indeed observed that the functionalization 
of nanowires by the integrin-binding mole-
cules improved MSCs adhesion significantly 
(Figure 11C), with increased cell area and 
formation of larger focal adhesions, which 
are required for bone formation. Notably, 
this effect was observed even on the spiky 
3 h anodization “coarse” nanowire surface, 
where very poor cell adhesion and prolif-
eration was initially found (Figure 10D).[277] 
Further, the study of osteogenic markers con-
firmed a moderate increase in osteogenesis 
on the αvβ3-integrin selective peptidomi-
metic-functionalized nanotopographies. Cru-
cially, the bactericidal properties of the high-
aspect-ratio nanotopographies have not been 
masked by the integrin-binding molecules.
Thus, the functionalization of nano-
structured surfaces with chemical coatings 
should be regarded as a way to improve 
their cell instructive properties, and offers 
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Figure 10. Immunofluorescence micrographs showing cell morphology and spread for BMSCs 
cultured on different bactericidal TiO2 nanotopographies. A) flat control, B) 2 h, C) 2.5 h, and 
D) 3 h surfaces (the length of anodization increasing nanowire size). Notable is that cells on 
the 2 h nanowires spread well—similar to on planar control. Red: actin, Green: tubulin, Blue: 
nucleus. Reproduced with permission under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International license (CC BY-NC-ND 4.0).[277] Copyright 
2014, the Authors. Published by Springer Nature.
Figure 11. A) Combining topographical and biochemical cues on the surface of biomaterials allows for a dual cell adhesive and antibacterial effect. 
B) Chemical structure of the synthetic ligands: αvβ3-selective (V3) or α5β1-selective (51) peptidomimetics,[70] and a peptidic platform combining 
RGD/PHSRN (P)[78,79]). C) Immunostained actin fibers and DAPI-stained nuclei for the flat control, fine and coarse nanotopographies functionalized 
with the three different integrin-binding molecules (V3, 51, or P). Scale bar = 100 µm. Adapted under the terms of the Creative Commons Attribution 
4.0 International license (CC BY 4.0).[297] Copyright 2017, the Authors. Published by Springer Nature.
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the possibility to further introduce a wide range of biological 
activities, which may not be always attainable by topography 
alone. We showed MSC response can be improved with inte-
grin-binding ligands, while keeping antimicrobial effects; but 
many other biochemical cues may be introduced, e.g., GFs 
and osteogenic peptides, mineralization sequences, and even 
AMPs or other antibacterial agents. These molecules may be 
incorporated using covalent (irreversible) approaches or drug-
releasing systems, as we have described in Sections 3.1 and 3.2. 
Another particularly relevant strategy would be to employ stim-
uli-responsive linkers, which could be cleaved upon enzymatic 
activity by either eukaryotic cells[298] or bacteria,[299] releasing or 
exposing the desired function in a dynamic and smart fashion. 
The possibilities are enormous and have not been investigated 
yet.
8. Conclusions
In this review we have shown that both chemical and topograph-
ical cues are potent modulators of the functions of eukaryotic 
and prokaryotic cells. In this regard, modifying the biomaterial 
surface properties to simultaneously enhance host cell adhe-
sion and function while inhibiting bacterial biofilm formation 
has been a major focus; we have reported recent strategies that 
demonstrate this is possible. However, as more efforts are put 
into developing novel methodologies, the number of challenges 
increases too.
In the first place, it is becoming evident that the biological 
evaluation of the osteoconductive and antibacterial poten-
tial of any new multifunctional surface will require the use 
of eukaryotic cell–bacteria cocultures, as the results obtained 
with the individual cell types may greatly differ from the more 
realistic, competitive scenario. In a recent study, we showed 
that bacteria directly inhibited the capacity of osteoblastic cells 
to spread and proliferate.[181] This study indicates that bac-
teria and cells not only race for the surface, but “fight for it,” 
and makes us postulate that the interactions between these 
two cell types and the biomaterial surface are better referred 
to as “the fight for the surface.” However, the mechanisms 
governing these interactions are not well understood, as the 
majority of current methods focus on the “finish line,”[14] but 
do not monitor the dynamic process of competition for the 
surface. Coupling biomaterials science with biosensing tech-
nologies could help to take a step forward to better under-
stand this process.
Achieving potent osteogenic effects on the biomaterial sur-
face is another challenge. Cell adhesive peptides such as RGD 
have shown moderate to poor outcomes in animal studies;[71–73] 
and the delivery of GFs like BMPs, while very effective in 
inducing bone formation, has raised concerns with regard to 
unwanted side effects, thus hampering its widespread clinical 
application.[90,91] Recent progress on developing multifunc-
tional systems synergizing integrin and GF signaling has 
shown it is possible to achieve excellent osteogenic responses 
in vitro and bone growth in vivo, with only very low doses of 
GFs.[86–89] Such systems may likely represent future strategies 
for implant-driven osteoinduction. The development of GF-
derived, short synthetic peptides and mimetics holds great 
potential too, and has not been fully explored. The combination 
of osteogenic peptides with antibacterial agents, like AMPs, has 
not been investigated either.
We have also discussed that an increasing concern in the 
medical device arena is the emergence of bacterial resistance. 
However, most approaches to fight infections on biomaterials 
still rely on the use of antibiotics. While it is true that newer 
systems of drug-delivery are being developed, with much 
better and improved release kinetics, replacement of antibi-
otics by other antibacterial systems, like the immobilization 
of AMPs, needs to be further studied. Moreover, some other 
frequent strategies used in biomaterials research present 
limitations too. This is the case, for example, of silver, one 
of the “gold standards” for use in antibacterial surfaces, but 
that presents toxicity for eukaryotic cells. In response to these 
limitations, innovations in genomics and the identification 
of new sources of antibacterial potential are being proposed 
to fill the classic antibacterial agents gap.[300,301] Interfering 
with bacterial quorum sensing communication is another 
emerging strategy with potential to inhibit biofilm formation 
on biomaterials.[302] Incorporation of such novel antibacterial 
drugs on biomaterials might well decrease the risk of bacterial 
resistance.
Finally, conferring osteogenic or antibacterial potential to 
surfaces by pure topographical effects opens up new and prom-
ising possibilities in GF-free and antibiotic-free medical thera-
pies. Further, achieving both effects by means of topography is 
a very promising avenue of research and we have shown this 
is feasible. However, we also acknowledge that this strategy 
may be limited in terms of bioactivity: the same way bacteria 
and eukaryotic cells are different in size and morphology, the 
nanopatterns that maximize one biological effect (e.g., osteo-
genesis) are in general different from those required to exert 
the other one (e.g., bacterial kill). This is illustrated by several 
antibacterial nanopatterns, such as high aspect-ratio surfaces, 
which effectively kill bacteria, but reduce MSCs functions at the 
same time. However, we have shown that chemical functionali-
zation of nanotopographies with integrin-binding molecules is 
a viable way to overcome this hurdle.[297] Thus, functionalizing 
nanotopographies with cell adhesive or antibacterial peptides 
opens new horizons toward highly cell instructive multifunc-
tional biomaterials. The physical bacterial killing mechanism 
represented by topography is likely to be more evolution 
resistant than drug-based strategies and the chemical approach 
can help drive osteogenesis while maintaining bacterial kill. 
This approach offers an unlimited combination of biological 
signals for a wide range of applications, and, interestingly, only 
now is starting to be investigated.
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